Supernus Pharmaceuticals Inc (SUPN)
34.09
+0.35
(+1.04%)
USD |
NASDAQ |
Mar 28, 16:00
34.09
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Cash from Financing (TTM): -397.88M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -397.88M |
September 30, 2023 | -396.14M |
June 30, 2023 | -389.46M |
March 31, 2023 | 91.73M |
December 31, 2022 | -10.48M |
September 30, 2022 | -150.05M |
June 30, 2022 | -155.18M |
March 31, 2022 | -154.70M |
December 31, 2021 | -130.42M |
September 30, 2021 | 9.389M |
June 30, 2021 | 7.086M |
March 31, 2021 | 5.774M |
December 31, 2020 | 3.559M |
September 30, 2020 | 1.753M |
June 30, 2020 | 2.974M |
March 31, 2020 | 3.177M |
December 31, 2019 | 3.928M |
September 30, 2019 | 3.916M |
June 30, 2019 | 4.502M |
March 31, 2019 | 9.508M |
December 31, 2018 | 376.44M |
September 30, 2018 | 376.36M |
June 30, 2018 | 377.88M |
March 31, 2018 | 372.79M |
December 31, 2017 | 5.681M |
Date | Value |
---|---|
September 30, 2017 | 5.307M |
June 30, 2017 | 3.221M |
March 31, 2017 | 2.532M |
December 31, 2016 | 2.052M |
September 30, 2016 | 2.055M |
June 30, 2016 | 1.853M |
March 31, 2016 | 1.844M |
December 31, 2015 | 1.867M |
September 30, 2015 | 1.373M |
June 30, 2015 | 31.33M |
March 31, 2015 | 30.71M |
December 31, 2014 | 30.57M |
September 30, 2014 | 28.81M |
June 30, 2014 | -1.222M |
March 31, 2014 | 63.76M |
December 31, 2013 | 62.74M |
September 30, 2013 | 106.57M |
June 30, 2013 | 104.36M |
March 31, 2013 | 87.95M |
December 31, 2012 | 87.92M |
September 30, 2012 | 60.43M |
June 30, 2012 | 61.34M |
March 31, 2012 | 13.42M |
December 31, 2011 | 27.09M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-397.88M
Minimum
Dec 2023
91.73M
Maximum
Mar 2023
-81.85M
Average
3.076M
Median
Cash from Financing (TTM) Benchmarks
Dynavax Technologies Corp | 1.386M |
Ligand Pharmaceuticals Inc | -59.95M |
Pacira BioSciences Inc | -183.03M |
Esperion Therapeutics Inc | 50.46M |
Collegium Pharmaceutical Inc | -140.18M |